Clinical Trial

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Enrolling by Invitation Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The current study is an investigator-initiated, single-arm phase 1/2 study that enrolled patients with advanced or recurrent and/or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma for the treatment of nal-IRI (ONIVYDE®) plus carboplatin as the first-line chemotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-05-17; most recent amendment 2025-08-14.
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-07-03
Trial Details
NCT Number NCT05385861
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital
Conditions GEP-NET
Enrollment 52 participants
Start Date 2025-08-14
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-15